Subscribe to RSS
DOI: 10.1055/s-0029-1219827
A Concise Synthesis of 6-Amino-6-deoxy-DNJ and 6-Amino-1,6-dideoxy-l-talonojirimycin
Publication History
Publication Date:
15 April 2010 (online)
Abstract
A concise and straightforward synthesis of two amino-DNJ derivatives, 6-amino-6-deoxy-DNJ and 6-amino-1,6-dideoxy-l-talonojirimycin is described from a commercial and cheap starting material. The methodology employed takes advantage of diastereoselective reductive amination to achieve the two non-natural iminosugars in three and five steps, respectively.
Key words
carbohydrates - inhibitors - alkaloids - azasugars - stereoselectivity
-
1a
Compain P.Martin OR. Iminosugars: From Synthesis to Therapeutic Applications Wiley & Sons; Chichester: 2007. -
1b
Bols M.Lillelund VH.Jensen HH.Liang X. Chem. Rev. 2002, 102: 515 -
1c
Zechel DL.Withers SG. Acc. Chem. Res. 2000, 33: 11 -
1d
Asano N.Nash RJ.Molyneux RJ.Fleet GWJ. Tetrahedron: Asymmetry 2000, 11: 1645 -
1e
Rye CS.Withers SG. Curr. Opin. Chem. Biol. 2000, 4: 573 -
1f
Iminosugars
as Glycosidase Inhibitors
Stütz AE. Wiley-VCH; Weinheim: 1999. -
1g
Vasella AT.Heightman TD. Angew. Chem. Int. Ed. 1999, 38: 750 -
1h
Withers SG.Namchuk M.Mosi R. In Iminosugars as glycosidase inhibitors: Nojirimicyn and BeyondStütz AE. Wiley-VCH; Weinheim: 1999. Chap. 9. p.188-206 -
1i
Sinnot ML. Chem. Rev. 1990, 90: 1171 -
1j
Bennet AJ.Sinnot ML. J. Am. Chem. Soc. 1986, 108: 7287 - For medical applications of iminosugars, see:
-
2a
Wrodnigg TM.Steiner AJ.Ueberbacher BJ. Anti-Cancer Agents Med. Chem. 2008, 8: 77 -
2b
Gerber-Lemaire S.Juillerat-Jeanneret L. Mini-Rev. Med. Chem. 2006, 6: 1043 -
2c
Robina I.Moreno-Vargas AJ.Carmona AT.Vogel P. Curr. Drug Metab. 2004, 5: 329 -
2d
Greimel P.Spreitz J.Stütz AE.Wrodnigg TM. Curr. Top. Med. Chem. 2003, 3: 513 -
2e
Fan J.-Q. Trends Pharmacol. Sci. 2003, 24: 355 -
2f
Asano N. Glycobiology 2003, 13: 93R -
2g Full issue, guest editors
Martin OR.Compain P. Curr. Top. Med. Chem. 2003, 3(5): -
2h
Watson AA.Fleet GWJ.Asano N.Molyneux RJ.Nash RJ. Phytochemistry 2001, 56: 265 -
2i
Butters TD.Dwek RA.Platt FM. Chem. Rev. 2000, 100: 4683 - For reviews, see:
-
3a
Afarinkia K.Bahar A. Tetrahedron: Asymmetry 2005, 16: 1239 -
3b
Pearson MSM.Mathé-Allainmat M.Fargeas V.Lebreton J. Eur. J. Org. Chem. 2005, 2159 -
3c
Ayad T.Genisson Y.Baltas M. Curr. Org. Chem. 2004, 8: 1211 -
3d
Weintraub PM.Sabol JS.Kane JM.Borcherding DR. Tetrahedron 2003, 59: 2953 -
3e
Dhavale DD.Desai VN.Saha NN.Tilekar JN. ARKIVOC 2002, (vii): 91 -
3f
Yoda H. Curr. Org. Chem. 2002, 6: 223 -
3g
Kazmaier U. Recent Res. Dev. Org. Chem. 1998, 2: 351 - For recent syntheses of DNJ, see:
-
6a
Danoun G.Ceccon J.Greene AE.Poisson J.-F. Eur. J. Org. Chem. 2009, 4221 -
6b
Racine E.Bello C.Gerber-Lemaire S.Vogel P.Py S. J. Org. Chem. 2009, 74: 1766 -
6c
Ruiz M.Ruanova TM.Blanco O.Núñez F.Pato C.Ojea V. J. Org. Chem. 2008, 73: 2240 -
6d
Malle BM.Lundt I.Wrodnigg TM. Org. Biomol. Chem. 2008, 6: 1779 -
6e
Zhou Y.Murphy PV. Org. Lett. 2008, 10: 3777 -
6f
Sugiyama M.Hong Z.Liang P.-H.Dean SM.Whalen LJ.Greenberg WA.Wong C.-H. J. Am. Chem. Soc. 2007, 129: 14811 -
6g
Kim IS.Lee HY.Jung YH. Heterocycles 2007, 71: 1787 -
6h
Song X.Hollingsworth RI. Tetrahedron Lett. 2007, 48: 3115 -
6i
Boucheron C.Compain P.Martin OR. Tetrahedron Lett. 2006, 47: 3081 -
6j
Thomassigny C.Barroso MT.Greck C. Lett. Org. Chem. 2005, 2: 316 -
6k
Tite T.Lallemand M.-C.Poupon E.Kunesch N.Tillequin F.Gravier-Pelletier C.Merrer YL.Husson H.-P. Bioorg. Med. Chem. 2004, 12: 5091 -
6l
Takahata H.Banba Y.Sasatani M.Nemoto H.Kato A.Adachi I. Tetrahedron 2004, 60: 8199 -
6m
McDonnell C.Cronin L.O’Brien JL.Murphy PV. J. Org. Chem. 2004, 69: 3565 -
6n
For selected syntheses of DNJ isomers, see ref. 6b, 6c and references therein, and refs 6d, 6f, 6g, 6h, and 6i
- See ref. 6j, and:
-
7a
Pampín MB.Fernández F.Estévez JC.Estévez RJ. Tetrahedron: Asymmetry 2009, 20: 503 -
7b
Poupon E.Luong B.-X.Chiaroni A.Kunesch N.Husson H.-P. J. Org. Chem. 2000, 65: 7208 -
7c
Kilonda A.Compernolle F.Peeters K.Joly GJ.Toppet S.Hoornaert GJ. Tetrahedron 2000, 56: 1005 -
7d
McCort I.Fort S.Dureault A.Depezay J.-C. Bioorg. Med. Chem. 2000, 8: 135 -
7e
Kilonda A.Compernolle F.Hoornaert GJ. J. Org. Chem. 1995, 60: 5820 -
7f
Kilonda A.Compernolle F.Toppet S.Hoornaert GJ. J. Chem. Soc., Chem. Commun. 1994, 2147 -
7g
Paulsen H.Steinert G. Chem. Ber. 1967, 100: 2467 -
8a
Lo Re D.Franco F.Sánchez-Cantalejo F.Tamayo JA. Eur. J. Org. Chem. 2009, 1984 -
8b
Izquierdo I.Tamayo JA.Rodríguez M.Franco F.Lo Re D. Tetrahedron 2008, 64: 7910 -
8c
Izquierdo I.Plaza MT.Tamayo JA.Mota JA. Synthesis 2004, 1083 -
8d
Izquierdo I.Plaza MT.Robles R.Mota AJ.Franco F. Tetrahedron: Asymmetry 2001, 12: 2749 - Starting material 8 was purchased from Carbosynth Limited (http://www.carbosynth.com). Alternatively, it can be synthesized as described in the following references:
-
9a
Meng X.-B.Li Y.-P.Li Z.-J. J. Chin. Pharm. Sci. 2007, 16: 43 -
9b
An J.-N.Meng X.-B.Yao Y.Li Z.-J. Carbohydr. Res. 2006, 341: 2200 -
9c
Lee CK. Carbohydr. Res. 1987, 170: 255 -
9d
Tokuyama K. Bull. Chem. Soc. Jpn. 1964, 37: 1133-1137 -
9e
Morgan WThJ.Reichstein T. Helv. Chim. Acta 1938, 21: 1023 -
11a
Izquierdo I.Plaza M.-T.Robles R.Mota AJ. Eur. J. Org. Chem. 2000, 2071 -
11b
Izquierdo I.Plaza M.-T.Robles R.Rodríguez C.Ramírez A.Mota AJ. Eur. J. Org. Chem. 1999, 1269 -
12a
von der Osten C.-H.Sinskey AJ.Barbas AF.Pederson RL.Wang Y.-F.Wong C.-H. J. Am. Chem. Soc. 1989, 111: 3924 -
12b
Kajimoto T.Chen L.Liu KK.-C.Wong C.-H. J. Am. Chem. Soc. 1991, 113: 6678
References and Notes
Zavesca® or Miglustat® (N-butyl-1-deoxynojirimycin) for Gaucher’s disease.
5Miglitol® [(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol] for diabetes.
10
Synthesis of (2
R
,3
R
,4
R
,5
S
)-2-(aminomethyl)-3,4,5-piperidinetriol
dihydrochloride [(6-amino-6-deoxy-DNJ) or (6-amino-1,5-imino-1,5,6-trideoxy-
d
-glucitol)
4] from diazido intermediate 6: A solution of 6 (206 mg, 0.76 mmol) in 50% aq
TFA (3 mL) was stirred at r.t. for 24 h. The mixture was evaporated
and codistilled with water and toluene several times. The final
residue was subjected to a short flash chromatography column (Et2O)
to give 10, which was used directly in
the next step without further purification. IR: 3399 (OH), 2109
(N3) cm-¹.
A solution
of compound 10 (142 mg, 0.62 mmol)in anhydrous
MeOH (20 mL) was hydrogenated at 60 psi over 10% Pd/C
(35 mg) for 24 h. The catalyst was filtered off, washed with MeOH
and the resulting filtrate evaporated. The residue was transferred
to a Dowex 50W×8 (200-400 mesh) column that was
eluted with MeOH (30 mL), H2O (20 mL) and 7% NH4OH
(40 mL), consecutively. After evaporation of the solvent the residue
was acidified with 10% aqueous HCl (10 mL) and then evaporated
to afford 4 (94 mg, 65% from 6) as a reddish foam; [α]D
²³ +10
(c 0.25, H2O). ¹H
NMR (500 MHz, D2O): δ = 3.67
(ddd, J
1,2 = 9.5, J
1
′
,2 = 11.8, J
2,3 = 5.2
Hz, 1 H, H-2), 3.56 (t, J
3,4 = J
4,5 = 9.3 Hz,
1 H, H-4), 3.49-3.37 (m, 4 H, H-1,3,5,6), 3.29 (dd, J
5,6 = 4.4, J
6,6
′ = 13.2
Hz, 1 H, H-6′), 2.90 (t, J
1,1
′ = 11.8
Hz, 1 H, H-1′). ¹³C NMR (125
MHz, D2O): δ = 78.3
(C-3), 73.5 (C-4), 68.9 (C-2), 57.8 (C-5), 48.8 (C-1), 41.9 (C-6).
HRMS (ES): m/z [M + H]+ calcd
for C6H15N2O3: 163.1083;
found: 163.1079
Synthesis of (2
S
,3
R
,4
S
,5
S
)-2-(aminomethyl)-3,4,5-piperidinetriol
dihydrochloride [(6-amino-1,6-dideoxy-
l
-
talo
nojirimycin)
or (6-amino-1,5-imino-1,5,6-trideoxy-
l
-talitol) 5] from
diazido intermediate 7: A solution of 7 (216
mg, 0.8 mmol) in 50% aqueous TFA (4 mL) was stirred at
r.t. for 18 h. The mixture was evaporated and codistilled with water
and toluene several times. The final residue was subjected to a
short flash chromatography column (Et2O) to give 12, which was used directly in the next
reaction without further purification. IR (KBr): 3391 (OH), 2106
(N3) cm-¹.
A solution
of compound 12 (95 mg, 0.41 mmol)in anhydrous MeOH
(20 mL) was hydrogenated at 60 psi over 10% Pd/C (25
mg) for 24 h. The catalyst was filtered off, washed with MeOH and
evaporated. The residue was transferred to a Dowex 50W×8
(200-400 mesh) column that was eluted with MeOH (30 mL),
H2O (20 mL) and 7% NH4OH (40 mL), consecutively.
After evaporation of the solvent, the residue was acidified with
10% aqueous HCl (10 mL) and then evaporated to afford 5 (71 mg, 73%) as a reddish foam; [α]D
²4 +33
(c 0.25, H2O).¹H
NMR (400 MHz, D2O): δ = 4.31 (br s,
2 H, H-2,4), 3.96 (t, J
3,4 = J
2,3 = 3.3
Hz, 1 H, H-3), 3.79 (m, 1 H, H-5), 3.67-3.59 (m, 2 H, H-1,6),
3.50 (dd, J
5,6 = 5.7, J
6,6
′ = 13.9
Hz, 1 H, H-6′), 3.40 (br d, 1 H, H-1′). ¹³C
NMR (100 MHz, D2O): δ = 70.2 (C-2 or
4), 69.5 (C-3), 68.4 (C-2 or 4), 58.3 (C-5), 51.0 (C-1), 40.6 (C-6).
HRMS (ES): m/z [M + H]+ calcd
for C6H15N2O3: 163.1083;
found: 163.1082